Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRebecca DaviesAGAnthony GreenwoodJWJack Watkins

Discussion

Loading...

Member takes

Overview

Survey shows disparities in awareness and access to T-cell therapies in patients with multiple myeloma, suggesting a need for improved patient advocacy.

Key Points

  • The study explores how race and socioeconomic factors affect the access to T-cell engaging therapies in patients with multiple myeloma.
  • Conducted 30-minute online surveys of 1301 patients with relapsed/refractory multiple myeloma across 7 countries
  • Analyzed results using descriptive statistics and chi-square tests
  • Focus on 305 US patients' responses regarding financial burden, employment, and education levels.
  • 47% of patients of color reported difficult financial circumstances compared to 26% of White patients
  • Lower rates of remission among patients of color (28%) compared to White patients (49%)
  • More employed patients had higher remission rates than unemployed patients (66% vs 24%).

Cite This Study

Davies et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7eehttps://doi.org/10.1182/blood-2025-2813
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access2025
  2. 2Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence2026
  3. 3Access to T-Cell Redirecting Therapies in Multiple Myeloma: Patient, Caregiver, and Physician Perspectives on Awareness and Barriers2026
  4. 4CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective2025
  5. 5Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities2025